Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621418 | 0.80 | FGFR1 (0.32) | FGFR1 | |
| SCHEMBL304399 | 0.72 | TYR (0.40) | ALDH1A1 | |
| SCHEMBL4120625 | 0.72 | LMNA (0.34) | ERN1ALDH1A1TLR2TLR1TLR6 | |
| SCHEMBL7717205 | 0.70 | UNG (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL4116944 | 0.69 | — | — | |
| SCHEMBL4979333 | 0.69 | ERN1 (0.33) | ERN1 | |
| SCHEMBL2305793 | 0.68 | KDM4E (0.33) | ALDH1A1L3MBTL1KDM4ETSHRTDP1 | |
| SCHEMBL7385049 | 0.68 | FPR2 (0.42) | ALDH1A1 | |
| SCHEMBL7852724 | 0.67 | — | — | |
| SCHEMBL1630844 | 0.67 | ADORA2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194046-B1 | Triazolone derivative | EISAI R&D MAN CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
| US-7928228-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2010-07-29 | — | — | US | disclosed |
| EP-2194046-A1 | Triazolone derivative | Eisai R&D Management Co., Ltd. (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2000465-A1 | TRIAZOLONE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | H1-0, H1-10, H1-2 | ERN1 1354/4885ALDH1A1 701/4885TLR2 3484/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | ERN1 1512/4885ALDH1A1 905/4885TLR2 3623/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | ERN1 1107/4885ALDH1A1 710/4885TLR2 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.